TauC3 Biologics Limited
Holborn
About TauC3 Biologics Limited
TAUC3BIO CORPORATION is a privately-held biopharmaceutical company focused on the development of innovative high precision immunotherapies for the treatment of tauopathies such as Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP). Its patented platform relates to the development of monoclonal antibodies (mAbs) targeting neurotoxic tau protein fragments, especially tauC3, with mAbs that do not bind to full-length tau (FLT). It was founded in 2019 and headquartered in Holborn, Camden.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.5M
- Funding stage: Seed
- Last round: Seed (Dec 2025)
- Website: tauc3bio.com
- Phone: 203-743-3938
Industries & Categories
Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/tauc3-biologics-limited-40839 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.